High Growth Tech Stocks Including Shanghai Henlius Biotech

As global markets experience fluctuations with major indexes like the Nasdaq Composite reaching new highs, small-cap stocks face challenges as evidenced by the Russell 2000's recent underperformance. Amidst these dynamics, high growth tech stocks such as Shanghai Henlius Biotech stand out by leveraging innovation and adaptability to navigate economic shifts and investor expectations.

Top 10 High Growth Tech Companies

Name	Revenue Growth	Earnings Growth	Growth Rating
Material Group	20.45%	24.01%	★★★★★★
Yggdrazil Group	30.20%	87.10%	★★★★★★
Seojin SystemLtd	35.41%	39.86%	★★★★★★
eWeLLLtd	27.24%	28.74%	★★★★★★
Medley	25.57%	31.67%	★★★★★★
Waystream Holding	22.09%	113.25%	★★★★★★
Mental Health TechnologiesLtd	25.83%	113.12%	★★★★★★
CD Projekt	24.92%	27.00%	★★★★★★
Fine M-TecLTD	36.52%	131.08%	★★★★★★
JNTC	29.48%	104.37%	★★★★★★

Click here to see the full list of 1267 stocks from our High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

Shanghai Henlius Biotech (SEHK:2696)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Shanghai Henlius Biotech, Inc. focuses on the research and development of biologic medicines targeting oncology, autoimmune diseases, and ophthalmic diseases, with a market cap of HK$12.96 billion.

Operations: Henlius generates revenue primarily from its pharmaceuticals segment, amounting to CN¥5.64 billion. The company is involved in the development of biologic medicines across key therapeutic areas.

Shanghai Henlius Biotech's recent advancements underscore its strategic focus on developing innovative therapies in the biotech sector. With a revenue growth of 9.8% and earnings growth forecast at 11.92% per year, the company is outpacing the Hong Kong market averages significantly, suggesting robust operational execution. Notably, its R&D efforts are pivotal, highlighted by the approval of HLX22 for phase 2 trials and HLX43 targeting PD-L1, positioning it at the forefront of cancer treatment innovations. These developments reflect a promising trajectory in addressing complex medical needs while expanding its influence in global markets through strategic product pipelines and clinical trials.

• Dive into the specifics of Shanghai Henlius Biotech here with our thorough health report.

• Gain insights into Shanghai Henlius Biotech's historical performance by reviewing our past performance report.

Visual China GroupLtd (SZSE:000681)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Visual China Group Co., Ltd. operates as an internet media service provider both in China and internationally, with a market capitalization of CN¥21 billion.

Operations: Visual China Group Co., Ltd. generates revenue through its internet media services, serving both domestic and international markets. The company leverages digital platforms to offer a range of media content and related services, contributing to its market presence in the industry.

Visual China GroupLtd has demonstrated resilience in a challenging market, with its revenue climbing to CNY 608.03 million from CNY 574.3 million year-over-year, reflecting a growth of 5.9%. Despite a downturn in net income from CNY 122.54 million to CNY 81.69 million, the company is poised for significant earnings growth, projected at an annual rate of 28.7%. This performance is underpinned by strategic amendments to its employee stock ownership plan and by-elections of independent directors aimed at bolstering governance and innovation within the firm's operations in interactive media and services—an industry where staying ahead technologically is crucial for maintaining competitive advantage.

• Delve into the full analysis health report here for a deeper understanding of Visual China GroupLtd.

• Gain insights into Visual China GroupLtd's past trends and performance with our Past report.

DeNA (TSE:2432)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: DeNA Co., Ltd. is a company that develops and operates mobile and online services globally, with a market capitalization of approximately ¥298.93 billion.

Operations: The company generates revenue primarily through its Game Business, Sports Businesses, Livestreaming Business, and Healthcare & Medical Business segments. The Game Business is the largest contributor with ¥50.20 billion in revenue, followed by the Livestreaming Business at ¥41.37 billion.

DeNA, navigating through a volatile market, is poised for significant growth with its revenue expected to rise by 4.8% annually. The company's strategic focus on R&D is evident from its substantial investment in innovation, crucial for staying competitive in the tech-driven market landscape. Despite current unprofitability, DeNA's earnings are projected to surge by 89.2% annually, underpinned by positive free cash flow and a shift towards profitability within three years. This forward-looking approach is supported by recent announcements such as the upcoming Q2 2025 results, signaling potential pivotal shifts in operational strategies and market positioning.

• Click to explore a detailed breakdown of our findings in DeNA's health report.

• Understand DeNA's track record by examining our Past report.

Turning Ideas Into Actions

• Navigate through the entire inventory of 1267 High Growth Tech and AI Stocks here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Searching for a Fresh Perspective?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com